UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
--------------------------------------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 7, 2005
--------------------------
PROVECTUS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Nevada 0-9410 90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of (Commission (I.R.S. Employer
Incorporation or Organization) File Number) Identification Number)
7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee 37931
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: 865/769-4011
--------------------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 8.01. Other Events.
Provectus Pharmaceuticals, Inc., announced that Professor John F Thompson, MD,
Director of the Sydney Melanoma Unit, Camperdown, NSW, Australia, discussed
preliminary results from the metastatic melanoma clinical trial he is conducting
using the Company's lead cancer agent, PV-10. Professor Thompson made his
remarks at The William and Ida Friday Center for Continuing Education of The
University of North Carolina at Chapel Hill on October 6, 2005, as part of the
course "Current Management of Melanoma: A Multidisciplinary Perspective." The
Company expects additional information on this clinical study (PV-10-MM-01,
details available at www.ClinicalTrials.gov) to be available in early 2006.
,
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Provectus Pharmaceuticals, Inc.
Dated: October 7, 2005 By:/s/ H. Craig Dees
------------------------------------------
H. Craig Dees
Chief Executive Officer